HDFC Mutual Fund disclosed a 1.07% stake in Biocon Limited, holding 1,73,61,624 shares as of the latest shareholding filing, up from under 1% in the prior quarter.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
One of India's oldest and most trusted AMCs with over Rs 7.5 lakh crore in AUM. Founded in 1999 as a joint venture between HDFC Bank and Standard Life. MD and CEO Navneet Munot, formerly CIO of SBI MF, has reinforced the quality and compounding philosophy across equity schemes. HDFC Flexi Cap Fund and HDFC Mid-Cap Opportunities Fund are among the largest actively managed equity schemes in India.
